SonoVue
sulphur hexafluoride
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for SonoVue. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use SonoVue.
For practical information about using SonoVue, patients should read the package leaflet or contact their doctor or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
SonoVue
|
Agency product number |
EMEA/H/C/000303
|
Active substance |
sulphur hexafluoride
|
International non-proprietary name (INN) or common name |
sulphur hexafluoride
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
V08DA04
|
Publication details | |
---|---|
Marketing-authorisation holder |
Bracco International B.V.
|
Revision |
20
|
Date of issue of marketing authorisation valid throughout the European Union |
26/03/2001
|
Contact address |
Strawinskylaan 3051
NL - 1077 ZX Amsterdam The Netherlands |
Product information
10/11/2022 SonoVue - EMEA/H/C/000303 - PSUSA/00002822/202009
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Contrast media
Therapeutic indication
This medicinal product is for diagnostic use only.
SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.
SonoVue should only be used in patients where study without contrast enhancement is inconclusive.
Echocardiography
SonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.
Doppler of macrovasculature
SonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.
SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.
Doppler of microvasculature
SonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.
Ultrasonography of excretory urinary tract
SonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography.